Trials / Completed
CompletedNCT00161642
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193. Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CMD-193 |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2005-09-12
- Last updated
- 2009-09-10
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00161642. Inclusion in this directory is not an endorsement.